should be correlated with our finding that TdT activity is also associated with increased survival and remission rates in acute non-lymphocytic leukaemia. We should emphasise that the TdT activity in our patients was low, which indirectly rules out that some with acute lymphocytic leukaemia had been misdiagnosed as having acute non-lymphocytic leukaemia. This is also supported by cytochemical and morphological analysis. The possibility still exists, however, that increased TdT activity indicates the presence of two blast populations, one lymphoid TdT-positive and a second myeloid or monocytic TdT-negative, as has been described by Mertelsmann et al. 15 We thus conclude that measurements of glucocorticoid receptor concentrations and TdT activity contribute partially independent prognostic information. When both are decreased a group of patients with a much decreased survival is identified.
In view of our findings we think that measurement of glucocorticoid receptor concentration and TdT activity should be considered in the design of future prospective studies of acute non-lymphocytic leukaemia.
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Hoffbrand A, Ganeshaguru K, Janossy G, Greaves Oral contraceptive steroid plasma concentrations in smokers and non-smokers
A study was performed to find out whether the overall rate of metabolism of oral contraceptives is affected by smoking and whether this explains the increased incidence of cardiovascular disease in users of oral contraceptives who smoke. Plasma ethinyloestradiol and norgestrel concentrations in 311 women using oral contraceptives were similar in smokers and non-smokers. users.' Tobacco smoke contains over 3000 chemicals and some of the constituents (polycyclic aromatic hydrocarbons) are enzyme-inducers. In pharmacokinetic studies the rate of metabolism of some drugs-for example, phenacetin and antipyrine-is increased in cigarette smokers. In contrast, no effect of smoking has been observed on the disposition of other drugs-for example, diazepam and phenytoin.' The metabolism of ethinyloestradiol may be important in relation to toxicity: a metabolite of ethinyloestradiol becomes irreversibly bound to protein of human hepatic microsomes,3 and this could be the starting point of an immunological mechanism leading to an adverse reaction. Consistent with this, anti-ethinyloestradiol antibodies have been detected in oral contraceptive users. 4 The aim of our study was twofold: to find out whether oral contraceptives fall into the group of drugs whose overall rate of metabolism is affected by smoking, and to see whether this might account for the increased toxicity.
Subjects, methods, and results
We studied 311 was separated by centrifugation and analysed for ethinyloestradiol and norgestrel content by radioimmunoassay. As an indicator of the absence or presence and extent of the smoking habit, the concentration of plasma thiocyanate was measured using a simple colorimetric assay. Statistical differences between the means were compared by using unpaired t tests and analysis of covariance. The table shows subjects grouped according to time since the pill was taken. There was no suggestion of a difference attributable to smoking in the mean ethinyloestradiol concentrations, even when subjected to a logarithmic (base 10) transformation to correct for a positive skew. The adjusted t value was derived from an analysis of covariance with the covariates being weight, age, and time (since the pill was taken). Norgestrel concentrations were not significantly different in the unpaired t test. When consideration was given to the differing amounts of norgestrel in the preparations (150 ,tg in Microgynon and Ovranette, 250 [g in Eugynon), and these data were subjected to analysis of covariance, again there was no significant difference between smokers and non-smokers. In all groups plasma thiocyanate concentrations were considerably increased. There was a similar large interindividual variation in plasma concentrations of ethinyloestradiol and norgestrel in both smokers and non-smokers (ethyinoestradiol: smokers 5-279 ng/l, non-smokers 5-450 ng/l; norgestrel: smokers 0-44-8 0 Ftg/l, non-smokers 0 25-5 38 ug/l).
Discussion
There was no suggestion of a difference due to smoking in plasma concentrations of either norgestrel or ethinyloestradiol, and contraceptive steroids therefore seem to fall into the group of drugs whose overall rate of metabolism is not altered by cigarette smoking. This does not, however, preclude the possibility of an increase in the rate of formation of a minor but potentially toxic metabolite. Gillette5 suggested that if under normal conditions the fraction of a drug converted into a reactive metabolite was small, then an enzyme inducer might considerably increase this fraction without any appreciable change in the plasma concentration or half life of the parent compound. Such a mechanism may operate in oral contraceptive users who smoke and hence give an increased incidence of toxicity. At present such a scheme is speculative and there is no firm evidence of a metabolic cause for the smoking-contraceptive steroid interaction. 
